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http://dx.doi.org/10.1016/j.jmii.2012Background: Antibiotics and anti-inflammatory agents are the mainstay of acute external otitis
(AEO) treatment. The present study investigated the effectiveness of a combination herbal
drop (Lamigex) composed of essential oils from Syzygium aromaticum, Lavandula angustifolia,
and Geranium robertianum in the alleviation of AEO symptoms and compared its effects to
those of ciprofloxacin 0.3% drop.
Methods: Seventy patients were randomly assigned to receive ciprofloxacin 0.3% (n Z 35) or
Lamigex (n Z 35) drop. Each group was administered with three drops every 12 hours for
a week. Patients were examined for AEO symptoms and ear discharge cultures at baselinejuries Research Center, Baqiyatallah University of Medical Sciences, Molla-Sadra Street, P.O. Box
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an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.10.002
212 Y. Panahi et al.Lavandula
angustifolia;
Pain;
Syzygium aromaticumas well as at the end of trial. Pain severity was also recorded using a visual analogue scale at
baseline, the 3rd day, and the 7th day of the trial.
Results: All assessed symptoms (tenderness, itching, erythema, edema and discharge) were
equally improved in the ciprofloxacin and Lamigex groups by the end of trial (p > 0.05). There
were remarkable reductions in the visual analogue scale score by the end of trial in both groups
(p < 0.001). However, the rate of pain improvement was not found to be significantly different
between the groups, either at the 3rd or 7th day of trial (p > 0.05). The numbers of positive
cultures for all tested microorganisms were clearly reduced by the end of the trial in both
groups but were not significantly different between the groups (p > 0.05).
Conclusion: The herbal combination drop that was investigated in the present study exhibited
good efficacy in reducing the burden of infection as well as AEO symptoms.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acute external otitis (AEO) refers to inflammation of the
external ear canal1,2 which affects four out of 100 people
every year.3 This disease occurs under certain conditions
involving temperature, humidity, and ambient water. The
chief complaint of patients is usually severe unilateral pain
and itching of the ear. In the early stages, AEO can cause
mild irritation with redness and slight edema in the ear
canal. However, at advanced stages, the symptoms would
be edema and increased secretions in the ear canal, and
might be accompanied by palpable adenopathy localized
around and behind the ears.
Severeedemaof the ear canal can cause loss of hearing.2e4
Pseudomonas aeruginosa is the most common pathogen for
AEO, being responsible for about 40% of illnesses, followed by
Staphylococcus aureus, which accounts for 9% of AEO cases.1
Other microorganisms such as S. epidermidis, Proteus
species, Streptococci, Enterococci, and other Gram-negative
bacilli as well as fungi (e.g., Candida albicans) have also been
reported fromAEOcultures.3e5 Thefirst step in treatingAEO is
the use of ototopical antibiotics. Other medications include
organic acids (e.g., 2% acetic acid) and anti-inflammatory
agents (e.g., betamethasone).2,3 Despite the widespread
use of ototopical antibiotics, bacterial resistance is an
important concern which necessitates the development of
novel therapeutic agents, especially those of natural origin.
Heretofore, numerous plants have been reported to possess
antibacterial, antiviral, and antifungal properties.6e12 Syzy-
gium aromaticum is a broad-spectrum antimicrobial, anti-
inflammatory, analgesic, and healing agent.13,14 Lavandula
angustifolia and Geranium robertianum are two other
medicinal plants which possess antimicrobial and anti-
inflammatory properties.15
In the present trial, the antimicrobial efficacy of
a combination herbal drop composed of essential oils from
S. aromaticum, L. angustifolia, and G. robertianum was
investigated in patients with AEO and compared to that of
ciprofloxacin, a widely used medication.
Materials and methods
The present study was a noninferiority trial that was
designed to indicate that the Lamigex combination herbaldrop is at least as effective as ciprofloxacin 0.3% drop (as
a standard and widely prescribed drug) in the alleviation of
AEO symptoms. Participants were patients aged 18e60
years who were referred to the ENT department of the
Baqiyatallah Hospital (Tehran, Iran) with initial AEO symp-
toms such as pain, itching, edema of the ear canal,
tenderness, or irregular ear discharge. Each patient filled
out a questionnaire, and the collected information was
compiled to study and compare the demographic and
laboratory data. The project was approved by the Baqiya-
tallah University of Medical Sciences (Tehran, Iran) ethics
committee, and written informed consent was obtained
from the patients.
Patients were randomly assigned to receive a cipro-
floxacin 0.3% drop or the herbal combination drop (under
the name Lamigex). Each group was administered with
three drops every 12 hours for a week. The active
ingredients of Lamigex drop were essential oils of
S. aromaticum, L. angustifolia, and G. robertianum,
which were prepared using a steam distillation method
and mixed in equal proportions.6e8,10 The drops were
used after cleansing the ear canal. Randomization was
performed individually, and patients were alternatively
allocated to treatments encoded as A or B, with the first
code being chosen randomly. The patients were
allowed to consume analgesics such as acetaminophen or
acetaminophen codeine, if necessary, instead of
using over-the-counter non-steroidal anti-inflammatory
drugs.
Patients were examined for tenderness, itching,
irregular discharge, redness, or edema of the ear canal at
baseline as well as at the end of trial. The pain score was
recorded using a visual analogue scale (VAS) at baseline,
the 3rd day, and the 7th day of the trial. The applied VAS
was designed as a 100-mm horizontal line without scaling,
in which 0 was marked as “no pruritus” and 100 was
marked as “unbearable pruritus.” Patients were then
instructed to place a vertical mark reflecting their
pruritus severity. Baseline and post-trial cultures of ear
discharge were also investigated. In case of no thera-
peutic response or worsening of symptoms, administration
of Lamigex was immediately discontinued; the patient
was then excluded and they subsequently underwent
standard treatment (three drops of topical ciprofloxacin
every 12 hours).
Table 1 Baseline and post-trial frequencies of ear discharge cultures in the study groups
Microorganism Ciprofloxacin Lamigex
Baseline 7th day Baseline 7th day
P. aeruginosa 8 (22.9%) 0 (0%) 11 (31.4%) 1 (2.9%)
S. aureus 9 (25.7%) 2 (5.7%) 10 (28.6%) 1 (2.9%)
S. epidermidis 7 (20%) 0 (0%) 8 (22.9%) 1 (2.9%)
Streptococcus spp. 4 (11.4%) 1 (2.9%) 3 (8.6%) 0 (0%)
Othera 7 (20%) 0 (0%) 3 (8.6%) 1 (2.9%)
Negative culture 0 (0%) 32 (91.4%)b 0 (0%) 31 (88.6%)c
a Including Escherichia coli, Entrococcus spp., etc.
b Statistical analyses did not reveal any significant difference in the post-trial frequencies of negative cultures between the groups
(p Z 1.00).
c There were significant reductions in the number of positive cultures in both groups (p < 0.001).
Values are number (%) of positive cultures for each microorganism.
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Data were analyzed using PASW 18 software and expressed
as mean  SD. Between-group comparisons were performed
using independent samples t-test (for continuous
variables), or chi-square and Fischer’s exact tests
(for categorical variables). Within-group comparisons
of VAS scores were made using repeated-measures ANOVA.
A p value of <0.05 was considered statistically significant.Results
Out of the 80 patients who were initially selected for the
study, 70 patients (35 in each group) completed the trial,
and their questionnaires were included in the final anal-
yses. Exclusion of patients was attributable to being lost to
follow-up and not completing the questionnaires. In the
ciprofloxacin group, there were 18 males (51.4%) and 17
females (48.6%), whereas 19 males (54.3%) and 16 females
(45.7%) completed the trial in the Lamigex group. The mean
age of patients was 37.11  8.59 and 37.29  8.65 years in
the ciprofloxacin and Lamigex group, respectively. A history
of external otitis was reported in 15 (42.9%) patients in the
ciprofloxacin group and 13 (37.1%) patients in the Lamigex
group, with no significant difference between the groupsTable 2 Baseline and post-trial frequencies of acute external o
Symptom Group Baseline p
Sa
Tenderness Ciprofloxacin 18 (51.4%) 0.225 0
Lamigex 23 (65.7%) 0
Itching Ciprofloxacin 32 (91.4%) 0.710 3
Lamigex 30 (85.7%) 1
Erythema Ciprofloxacin 24 (68.6%) 0.163 0
Lamigex 29 (82.9%) 0
Edema Ciprofloxacin 17 (48.6%) 0.743 0
Lamigex 20 (57.1%) 0
Discharge Ciprofloxacin 28 (80%) 0.894 0
Lamigex 29 (86.9%) 1
Values are expressed as number (%) of individuals with the respective(p Z 0.626). In these patients, the interval between the
last occurrence of external otitis and current AEO was not
significantly different (3.71  5.25 and 3.03  5.38 months
in the ciprofloxacin and Lamigex groups, respectively;
p Z 0.602). Likewise, the interval between the onset of
symptoms and seeing a physician did not differ between the
groups (5.66  2.76 and 5.37  3.13 days in the cipro-
floxacin and Lamigex groups, respectively; p Z 0.687).
The frequencies of positive ear discharge cultures for
different pathogenic bacteria are summarized in Table 1.
Overall, the numbers of positive cultures for all tested
microorganisms were clearly reduced by the end of trial in
both groups (p < 0.001). The number of positive cultures at
the end of trial was not significantly different between the
groups (p Z 1.00).
The groups were comparable in their frequencies of
baseline AEO symptoms including tenderness (p Z 0.225),
itching (p Z 0.710), erythema (p Z 0.163), edema
(p Z 0.743), and discharge (p Z 0.894). The improvement
of AEO symptoms was evaluated at the end of trial. Inter-
estingly, all assessed symptoms were equally improved in
ciprofloxacin and Lamigex groups by the end of trial
(p Z 0.678, 0.626, 0.728, 0.462, and 0.415 for tenderness,
itching, erythema, edema, and discharge, respectively)
(Table 2). In the same manner, there was no significant
difference between the groups regarding the rate of paintitis symptoms in the study groups
Post-trial severity p
me Reduced Completely recovered
(0%) 9 (50%) 9 (50%) 0.678
(0%) 10 (43.5%) 13 (56.5%)
(9.4%) 12 (37.5%) 17 (53.1%) 0.626
(3.3%) 12 (40%) 17 (56.7%)
(0%) 8 (33.3%) 16 (66.7%) 0.728
(0%) 11 (37.9%) 18 (62.1%)
(0%) 3 (17.6%) 14 (82.4%) 0.462
(0%) 6 (30%) 14 (70%)
(0%) 6 (42.9%) 8 (57.1%) 0.415
(6.2%) 9 (56.3%) 6 (37.5%)
symptom.
Table 3 Frequency of ear pain in the study groups at different time points
Ciprofloxacin Lamigex p
Baseline 17 (48.6%) 19 (54.3%) 0.632
Day 3 Same 1 (5.9%) 2 (10.5%) 0.855
Reduced 11 (64.7%) 11 (57.9%)
Completely recovered 5 (29.4%) 6 (31.6%)
Day 7 Same 0 (0%) 0 (0%) 0.543
Reduced 5 (41.7%) 7 (53.8%)
Completely recovered 7 (58.3%) 6 (46.2%)
Values are expressed as number (%).
214 Y. Panahi et al.recovery by either the 3rd (pZ 0.855) or the 7th (pZ 0.543)
day of the trial (Table 3). Among patients with ear pain, the
VAS score was not significantly different between Cipro-
floxacin and Lamigex groups at baseline (pZ 0.900) as well
as the 3rd (p Z 0.841) and the 7th (p Z 0.957) day of the
trial (Fig. 1). However, both groups experienced significant
reductions in VAS score and pain severity by the end of the
trial (p < 0.001) (Fig. 1). The reductions in VAS score in
different intervals of the study (days 1e3, 3e7 and 1e7)
were also compared between the ciprofloxacin and Lamigex
groups. The magnitude of reductions in VAS score was not
significantly different between the groups at any of the
intervals [days 1e3 (pZ 0.990), days 3e7 (pZ 0.820), and
days 1e7 (p Z 0.909)] (Fig. 2).Discussion
In order to develop novel medications for AEO, several
prerequisites must be met. The most important issues are
sufficient coverage of pathogenic microorganisms, and lack
of bacterial resistance,17 allergic reactions, and ototox-
icity.18 One of the most important concerns about the use
of ototopical antibiotics is the development of bacterialFigure 1. Comparison of visual analogue scale (VAS)resistance. Therefore, introduction of herbal preparations
with equal efficacy to the currently administered antibi-
otics is highly desirable to be used alone or in combination
with current medications for the purpose of dose reduction
and resistance prevention.
In the current study, the combination herbal drop con-
taining essential oils of S. aromaticum, L. angustifolia, and
G. robertianum was found to be as effective as cipro-
floxacin 0.3% in terms of antibiotic effects as well as
reducing AEO-associated pain and symptoms (tenderness,
itching, erythema, edema, and discharge).
Clove oil is endowed with multiple medicinal benefits
including carminative, antinausea, antivomiting, mouth
freshening, analgesic, and sedative effects.6,14,19 Apart
from these effects, clove oil has potent antimicrobial
activities against a range of microorganisms such as
S. aureus, Klebsiella pneumonia, Escherichia coli, Entero-
coccus faceum, and C. albicans.17e22 Eugenol is the main
aromatic component of the clove oil, which is involved in
the antimicrobial effects of clove oil.20,21
Lavender oil is a well-known and widely used oil which
has a broad application in the hygienic and cosmeceutical
industries.22e24 This oil has been the subject of numerous
research studies in the past years. These investigationsscore between Ciprofloxacin and Lamigex groups.
Figure 2. Comparison of the magnitude of reduction in VAS score between Ciprofloxacin and Lamigex groups.
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including spasmolytic, local anesthetizing, antioxidant, and
antibacterial properties.24e29 Linalool is among the active
components of lavender oil which is responsible, at least in
part, for the antimicrobial and antifungal properties.30
Geraniol and citronellol are the main ingredients of
G. robertianum oil and have remarkable antifungal activity
against the clinical isolates of C. albicans. This oil also has
fungicidal activity against the toxigenic strains of Asper-
gillus flavus and prevents aflatoxin production. The anti-
fungal activity of geraniol might be attributed to the
induction of potassium efflux from the cell and increasing
the fluidity of C. albicans membrane. Aside from antifungal
activity, G. robertianum oil has also been shown to exert
antibacterial activity against a wide range of Gram-positive
and Gram-negative bacteria including S. aureus, P. vulga-
ris, Bacillus cereus, S. epidermidis, Streptococcus pneu-
monia, K. pneumonia, E. coli, P. aeruginosa, and
vancomycin-resistant Enterococcus species.6,15,16
Overall, the herbal combination drop investigated in this
study exhibited good efficacy in reducing the burden of
infection as well as alleviating AEO symptoms. This finding
is especially important when considering the superiority of
ciprofloxacin to a number of medications used for the
management of AEO. In previous studies, ciprofloxcacin has
been demonstrated to have equal or better efficacy
compared to classic antibioticesteroid combination drugs
such as oxytetracyclineepolymixin Behydrocortisone and
neomycinepolymixin Behydrocortisone.31e33 However,
further research is warranted to confirm the efficacy of this
combination drop in a larger study population. In addition,
longer follow-up durations are necessary to assess the
possible adverse effects of this drug.
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